Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has seen a rise in its stock price by 1.97 in relation to its previous close of 17.80. However, the company has experienced a 0.22% gain in its stock price over the last five trading sessions. Investopedia reported 2024-03-12 that Shares of Acadia Pharmaceuticals (ACAD) plunged more than 16% Tuesday after one of its current drugs failed to meet its goal for expanded use in a Phase 3 trial.
Is It Worth Investing in Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Right Now?
The 36-month beta value for ACAD is also noteworthy at 0.40. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for ACAD is 163.49M, and at present, short sellers hold a 6.50% of that float. The average trading volume of ACAD on April 10, 2024 was 1.84M shares.
ACAD’s Market Performance
ACAD stock saw a decrease of 0.22% in the past week, with a monthly decline of -22.57% and a quarterly a decrease of -39.76%. The volatility ratio for the week is 2.89%, and the volatility levels for the last 30 days are 3.44% for Acadia Pharmaceuticals Inc (ACAD). The simple moving average for the last 20 days is -3.02% for ACAD stock, with a simple moving average of -27.46% for the last 200 days.
Analysts’ Opinion of ACAD
Many brokerage firms have already submitted their reports for ACAD stocks, with Needham repeating the rating for ACAD by listing it as a “Buy.” The predicted price for ACAD in the upcoming period, according to Needham is $32 based on the research report published on March 12, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see ACAD reach a price target of $25, previously predicting the price at $39. The rating they have provided for ACAD stocks is “Neutral” according to the report published on March 12th, 2024.
Robert W. Baird gave a rating of “Outperform” to ACAD, setting the target price at $40 in the report published on January 30th of the current year.
ACAD Trading at -19.66% from the 50-Day Moving Average
After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.60% of loss for the given period.
Volatility was left at 3.44%, however, over the last 30 days, the volatility rate increased by 2.89%, as shares sank -24.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.63% lower at present.
During the last 5 trading sessions, ACAD rose by +0.22%, which changed the moving average for the period of 200-days by -24.50% in comparison to the 20-day moving average, which settled at $18.42. In addition, Acadia Pharmaceuticals Inc saw -42.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACAD starting from DAVIS STEPHEN, who sale 26,574 shares at the price of $17.87 back on Apr 08 ’24. After this action, DAVIS STEPHEN now owns 144,267 shares of Acadia Pharmaceuticals Inc, valued at $474,877 using the latest closing price.
Schneyer Mark C., the EVP, CHIEF FINANCIAL OFFICER of Acadia Pharmaceuticals Inc, sale 2,716 shares at $17.87 during a trade that took place back on Apr 08 ’24, which means that Schneyer Mark C. is holding 28,742 shares at $48,535 based on the most recent closing price.
Stock Fundamentals for ACAD
Current profitability levels for the company are sitting at:
- -0.1 for the present operating margin
- 0.94 for the gross margin
The net margin for Acadia Pharmaceuticals Inc stands at -0.08. The total capital return value is set at -0.15. Equity return is now at value -14.73, with -9.17 for asset returns.
Based on Acadia Pharmaceuticals Inc (ACAD), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at 0.29. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is 8.09.
Currently, EBITDA for the company is -67.83 million with net debt to EBITDA at 1.83. When we switch over and look at the enterprise to sales, we see a ratio of 3.94. The receivables turnover for the company is 7.1for trailing twelve months and the total asset turnover is 0.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.42.
Conclusion
In summary, Acadia Pharmaceuticals Inc (ACAD) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
